title: [Description of a peculiar form of Hodgkin's disease associated with Epstein-Barr virus infection].
abstract: The authors report a peculiar form of Hodgkin's disease that is associated with Epstein-Barr virus infection. A 16-year-old patient was admitted for an autoimmune haemolytic anaemia associated with IgG auto-immune antibodies, linked to general clinical complications, cervical adenopathies and splenomegalia. The patient underwent hemicavectomy that was not histologically investigated. The ganglionar exeresis helped to establish the histological diagnosis of Hodgkin's disease, classic form with nodular sclerosis. Tumour cells were CD30 CD15 positive and neighbouring lymphoid cells were CD3 and CD20 positive. In situ hybridation allowed the detection of Epstein-Barr virus in tumour cells. Under ABVD chemotherapy supplemented with acyclovir and initial corticotherapy, mid-treatment evolution appears to be favourable. This observation is consistent with the hypothesis that tumour cells are of B cell origin during Hodgkin's disease, together with the involvement of Epstein-Barr virus in lymphomagenesis.
authors.affiliation: Service d'hématologie, CHU de Brazzaville, BP 13027, Brazzaville, République du Congo. dokekias@yahoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Elira Dokekias
authors.forename: I
authors.initials: I
authors.lastname: Koko
authors.forename: F O
authors.initials: FO
authors.lastname: Atipo Galiba
authors.forename: A
authors.initials: A
authors.lastname: Martin
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis*; D006689:Hodgkin Disease / Q000821:virology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D014412:Tumor Virus Infections / Q000175:diagnosis*; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D000998:Antiviral Agents; D001323:Autoantibodies; D007074:Immunoglobulin G; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D000212:Acyclovir